APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Pain Management Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Pain Management Drug Market Analysis and Forecast 2026-2032

Report ID 173999950222 December 2025219 pages

Choose your research edition.

Industry ResearchHuman Pain Management Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Pain Management Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Human Pain Management Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Pain Management Drug Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Pain Management Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Human Pain Management Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Pain Management Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Pain Management Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Pain Management Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Pain Management Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human Pain Management Drug include Teva Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Novartis AG, Pfizer Inc., GSK plc., Bayer AG and Bristol Myers Squibb Co., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Pain Management Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Pain Management Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Pain Management Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Pain Management Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Pain Management Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Pain Management Drug revenue, projected growth trends, production technology, application and end-user industry.

Human Pain Management Drug Segment by Company

Teva Pharmaceuticals Ltd.

Sun Pharmaceutical Industries Ltd.

Sanofi S.A.

Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Novartis AG

Pfizer Inc.

GSK plc.

Bayer AG

Bristol Myers Squibb Co.

AbbVie Inc. (Allergan plc)

AstraZeneca

Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)

Viatris

Purdue Pharmaceuticals L.P.

Procter & Gamble

Perrigo Company Plc.

Mallinckrodt Pharmaceuticals

F. Hoffmann-La Roche Ltd.

Endo Pharmaceuticals Inc.

Cardinal Health

Boehringer Ingelheim International GmbH

Bausch Health Companies Inc.

Amneal Pharmaceuticals

Abbott Laboratories, Inc.

Human Pain Management Drug Segment by Type

OTC

Rx

Human Pain Management Drug Segment by Application

Hospital

Retail Pharmacy

Other

Human Pain Management Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Pain Management Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Pain Management Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Pain Management Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Pain Management Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Pain Management Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Pain Management Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Pain Management Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. OTC Major Player Table 3. Rx Major Player Table 4. Global Human Pain Management Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Retail Pharmacy Major Player Table 7. Other Major Player Table 8. Human Pain Management Drug Industry Trends Table 9. Human Pain Management Drug Industry Drivers Table 10. Human Pain Management Drug Industry Opportunities and Challenges Table 11. Human Pain Management Drug Industry Restraints Table 12. Global Human Pain Management Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Human Pain Management Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Human Pain Management Drug Market Share by Region (2021-2026) Table 15. Global Human Pain Management Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Human Pain Management Drug Market Share by Region (2027-2032) Table 17. Global Human Pain Management Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Human Pain Management Drug Revenue Market Share by Players (2021-2026) Table 19. Global Human Pain Management Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Human Pain Management Drug Key Players Headquarters & Area Served Table 21. Global Human Pain Management Drug Players, Product Type & Application Table 22. Global Human Pain Management Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Human Pain Management Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Human Pain Management Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Human Pain Management Drug Revenue Market Share by Type (2021-2026) Table 29. Global Human Pain Management Drug Revenue Market Share by Type (2027-2032) Table 30. Global Human Pain Management Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Human Pain Management Drug Revenue Market Share by Application (2021-2026) Table 34. Global Human Pain Management Drug Revenue Market Share by Application (2027-2032) Table 35. Teva Pharmaceuticals Ltd. Company Information Table 36. Teva Pharmaceuticals Ltd. Business Overview Table 37. Teva Pharmaceuticals Ltd. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Teva Pharmaceuticals Ltd. Human Pain Management Drug Product Portfolio Table 39. Teva Pharmaceuticals Ltd. Recent Development Table 40. Sun Pharmaceutical Industries Ltd. Company Information Table 41. Sun Pharmaceutical Industries Ltd. Business Overview Table 42. Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Product Portfolio Table 44. Sun Pharmaceutical Industries Ltd. Recent Development Table 45. Sanofi S.A. Company Information Table 46. Sanofi S.A. Business Overview Table 47. Sanofi S.A. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sanofi S.A. Human Pain Management Drug Product Portfolio Table 49. Sanofi S.A. Recent Development Table 50. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Company Information Table 51. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Business Overview Table 52. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Product Portfolio Table 54. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Recent Development Table 55. Novartis AG Company Information Table 56. Novartis AG Business Overview Table 57. Novartis AG Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Novartis AG Human Pain Management Drug Product Portfolio Table 59. Novartis AG Recent Development Table 60. Pfizer Inc. Company Information Table 61. Pfizer Inc. Business Overview Table 62. Pfizer Inc. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Pfizer Inc. Human Pain Management Drug Product Portfolio Table 64. Pfizer Inc. Recent Development Table 65. GSK plc. Company Information Table 66. GSK plc. Business Overview Table 67. GSK plc. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GSK plc. Human Pain Management Drug Product Portfolio Table 69. GSK plc. Recent Development Table 70. Bayer AG Company Information Table 71. Bayer AG Business Overview Table 72. Bayer AG Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Bayer AG Human Pain Management Drug Product Portfolio Table 74. Bayer AG Recent Development Table 75. Bristol Myers Squibb Co. Company Information Table 76. Bristol Myers Squibb Co. Business Overview Table 77. Bristol Myers Squibb Co. Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Bristol Myers Squibb Co. Human Pain Management Drug Product Portfolio Table 79. Bristol Myers Squibb Co. Recent Development Table 80. AbbVie Inc. (Allergan plc) Company Information Table 81. AbbVie Inc. (Allergan plc) Business Overview Table 82. AbbVie Inc. (Allergan plc) Human Pain Management Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. AbbVie Inc. (Allergan plc) Human Pain Management Drug Product Portfolio Table 84. AbbVie Inc. (Allergan plc) Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. AstraZeneca Human Pain Management Drug Product Portfolio Table 89. AstraZeneca Recent Development Table 90. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Company Information Table 91. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Business Overview Table 92. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Product Portfolio Table 94. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Recent Development Table 95. Viatris Company Information Table 96. Viatris Business Overview Table 97. Viatris Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Viatris Human Pain Management Drug Product Portfolio Table 99. Viatris Recent Development Table 100. Purdue Pharmaceuticals L.P. Company Information Table 101. Purdue Pharmaceuticals L.P. Business Overview Table 102. Purdue Pharmaceuticals L.P. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Purdue Pharmaceuticals L.P. Human Pain Management Drug Product Portfolio Table 104. Purdue Pharmaceuticals L.P. Recent Development Table 105. Procter & Gamble Company Information Table 106. Procter & Gamble Business Overview Table 107. Procter & Gamble Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Procter & Gamble Human Pain Management Drug Product Portfolio Table 109. Procter & Gamble Recent Development Table 110. Perrigo Company Plc. Company Information Table 111. Perrigo Company Plc. Business Overview Table 112. Perrigo Company Plc. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Perrigo Company Plc. Human Pain Management Drug Product Portfolio Table 114. Perrigo Company Plc. Recent Development Table 115. Mallinckrodt Pharmaceuticals Company Information Table 116. Mallinckrodt Pharmaceuticals Business Overview Table 117. Mallinckrodt Pharmaceuticals Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Mallinckrodt Pharmaceuticals Human Pain Management Drug Product Portfolio Table 119. Mallinckrodt Pharmaceuticals Recent Development Table 120. F. Hoffmann-La Roche Ltd. Company Information Table 121. F. Hoffmann-La Roche Ltd. Business Overview Table 122. F. Hoffmann-La Roche Ltd. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. F. Hoffmann-La Roche Ltd. Human Pain Management Drug Product Portfolio Table 124. F. Hoffmann-La Roche Ltd. Recent Development Table 125. Endo Pharmaceuticals Inc. Company Information Table 126. Endo Pharmaceuticals Inc. Business Overview Table 127. Endo Pharmaceuticals Inc. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Endo Pharmaceuticals Inc. Human Pain Management Drug Product Portfolio Table 129. Endo Pharmaceuticals Inc. Recent Development Table 130. Cardinal Health Company Information Table 131. Cardinal Health Business Overview Table 132. Cardinal Health Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Cardinal Health Human Pain Management Drug Product Portfolio Table 134. Cardinal Health Recent Development Table 135. Boehringer Ingelheim International GmbH Company Information Table 136. Boehringer Ingelheim International GmbH Business Overview Table 137. Boehringer Ingelheim International GmbH Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Boehringer Ingelheim International GmbH Human Pain Management Drug Product Portfolio Table 139. Boehringer Ingelheim International GmbH Recent Development Table 140. Bausch Health Companies Inc. Company Information Table 141. Bausch Health Companies Inc. Business Overview Table 142. Bausch Health Companies Inc. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. Bausch Health Companies Inc. Human Pain Management Drug Product Portfolio Table 144. Bausch Health Companies Inc. Recent Development Table 145. Amneal Pharmaceuticals Company Information Table 146. Amneal Pharmaceuticals Business Overview Table 147. Amneal Pharmaceuticals Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Amneal Pharmaceuticals Human Pain Management Drug Product Portfolio Table 149. Amneal Pharmaceuticals Recent Development Table 150. Abbott Laboratories, Inc. Company Information Table 151. Abbott Laboratories, Inc. Business Overview Table 152. Abbott Laboratories, Inc. Human Pain Management Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 153. Abbott Laboratories, Inc. Human Pain Management Drug Product Portfolio Table 154. Abbott Laboratories, Inc. Recent Development Table 155. North America Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. North America Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. North America Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. North America Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. North America Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Human Pain Management Drug Revenue by Country (2021-2026) & (US$ Million) Table 161. North America Human Pain Management Drug Revenue by Country (US$ Million) & (2027-2032) Table 162. Europe Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 163. Europe Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 164. Europe Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 165. Europe Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 166. Europe Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. Europe Human Pain Management Drug Revenue by Country (2021-2026) & (US$ Million) Table 168. Europe Human Pain Management Drug Revenue by Country (US$ Million) & (2027-2032) Table 169. China Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 170. China Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 171. China Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. China Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 174. Asia Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 175. Asia Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 176. Asia Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 177. Asia Human Pain Management Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 178. Asia Human Pain Management Drug Revenue by Region (US$ Million) & (2021-2026) Table 179. Asia Human Pain Management Drug Revenue by Region (US$ Million) & (2027-2032) Table 180. SAMEA Human Pain Management Drug Revenue by Type (2021-2026) & (US$ Million) Table 181. SAMEA Human Pain Management Drug Revenue by Type (2027-2032) & (US$ Million) Table 182. SAMEA Human Pain Management Drug Revenue by Application (2021-2026) & (US$ Million) Table 183. SAMEA Human Pain Management Drug Revenue by Application (2027-2032) & (US$ Million) Table 184. SAMEA Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. SAMEA Human Pain Management Drug Revenue by Country (2021-2026) & (US$ Million) Table 186. SAMEA Human Pain Management Drug Revenue by Country (US$ Million) & (2027-2032) Table 187. Research Programs/Design for This Report Table 188. Authors List of This Report Table 189. Secondary Sources Table 190. Primary Sources List of Figures Figure 1. Human Pain Management Drug Image Figure 2. Global Human Pain Management Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Pain Management Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. OTC Image Figure 5. Rx Image Figure 6. Global Human Pain Management Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Human Pain Management Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Retail Pharmacy Image Figure 10. Other Image Figure 11. Global Human Pain Management Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Human Pain Management Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Human Pain Management Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Human Pain Management Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Human Pain Management Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Human Pain Management Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Human Pain Management Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Human Pain Management Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Human Pain Management Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Human Pain Management Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Human Pain Management Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Human Pain Management Drug Revenue Share by Type (2021-2032) Figure 24. North America Human Pain Management Drug Revenue Share by Application (2021-2032) Figure 25. North America Human Pain Management Drug Revenue Share by Country (2021-2032) Figure 26. United States Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Human Pain Management Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Human Pain Management Drug Revenue Share by Type (2021-2032) Figure 31. Europe Human Pain Management Drug Revenue Share by Application (2021-2032) Figure 32. Europe Human Pain Management Drug Revenue Share by Country (2021-2032) Figure 33. Germany Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Human Pain Management Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Human Pain Management Drug Revenue Share by Type (2021-2032) Figure 43. China Human Pain Management Drug Revenue Share by Application (2021-2032) Figure 44. Asia Human Pain Management Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Human Pain Management Drug Revenue Share by Type (2021-2032) Figure 46. Asia Human Pain Management Drug Revenue Share by Application (2021-2032) Figure 47. Asia Human Pain Management Drug Revenue Share by Region (2021-2032) Figure 48. Japan Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Human Pain Management Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Human Pain Management Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Human Pain Management Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Human Pain Management Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Human Pain Management Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Teva Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Novartis AG
  • Pfizer Inc.
  • GSK plc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • AbbVie Inc. (Allergan plc)
  • AstraZeneca
  • Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
  • Viatris
  • Purdue Pharmaceuticals L.P.
  • Procter & Gamble
  • Perrigo Company Plc.
  • Mallinckrodt Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Endo Pharmaceuticals Inc.
  • Cardinal Health
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Amneal Pharmaceuticals
  • Abbott Laboratories, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Pain Management Drug Market by Type
  3. 1.2.1 Global Human Pain Management Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 OTC
  5. 1.2.3 Rx
  6. 1.3 Human Pain Management Drug Market by Application
  7. 1.3.1 Global Human Pain Management Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Human Pain Management Drug Market Dynamics
  1. 2.1 Human Pain Management Drug Industry Trends
  2. 2.2 Human Pain Management Drug Industry Drivers
  3. 2.3 Human Pain Management Drug Industry Opportunities and Challenges
  4. 2.4 Human Pain Management Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Pain Management Drug Market Perspective (2021-2032)
  2. 3.2 Global Human Pain Management Drug Growth Trends by Region
  3. 3.2.1 Global Human Pain Management Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Pain Management Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Pain Management Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Pain Management Drug Revenue by Players
  2. 4.1.1 Global Human Pain Management Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Pain Management Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Pain Management Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Pain Management Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Pain Management Drug Key Players Headquarters & Area Served
  7. 4.4 Global Human Pain Management Drug Players, Product Type & Application
  8. 4.5 Global Human Pain Management Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Pain Management Drug Market CR5 and HHI
  11. 4.6.3 2025 Human Pain Management Drug Tier 1, Tier 2, and Tier 3
5 Human Pain Management Drug Market Size by Type
  1. 5.1 Global Human Pain Management Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Pain Management Drug Revenue by Type (2021-2032)
  3. 5.3 Global Human Pain Management Drug Revenue Market Share by Type (2021-2032)
6 Human Pain Management Drug Market Size by Application
  1. 6.1 Global Human Pain Management Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Pain Management Drug Revenue by Application (2021-2032)
  3. 6.3 Global Human Pain Management Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceuticals Ltd.
  2. 7.1.1 Teva Pharmaceuticals Ltd. Company Information
  3. 7.1.2 Teva Pharmaceuticals Ltd. Business Overview
  4. 7.1.3 Teva Pharmaceuticals Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceuticals Ltd. Human Pain Management Drug Product Portfolio
  6. 7.1.5 Teva Pharmaceuticals Ltd. Recent Developments
  7. 7.2 Sun Pharmaceutical Industries Ltd.
  8. 7.2.1 Sun Pharmaceutical Industries Ltd. Company Information
  9. 7.2.2 Sun Pharmaceutical Industries Ltd. Business Overview
  10. 7.2.3 Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharmaceutical Industries Ltd. Human Pain Management Drug Product Portfolio
  12. 7.2.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  13. 7.3 Sanofi S.A.
  14. 7.3.1 Sanofi S.A. Company Information
  15. 7.3.2 Sanofi S.A. Business Overview
  16. 7.3.3 Sanofi S.A. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi S.A. Human Pain Management Drug Product Portfolio
  18. 7.3.5 Sanofi S.A. Recent Developments
  19. 7.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  20. 7.4.1 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Company Information
  21. 7.4.2 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Business Overview
  22. 7.4.3 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Human Pain Management Drug Product Portfolio
  24. 7.4.5 Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Recent Developments
  25. 7.5 Novartis AG
  26. 7.5.1 Novartis AG Company Information
  27. 7.5.2 Novartis AG Business Overview
  28. 7.5.3 Novartis AG Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis AG Human Pain Management Drug Product Portfolio
  30. 7.5.5 Novartis AG Recent Developments
  31. 7.6 Pfizer Inc.
  32. 7.6.1 Pfizer Inc. Company Information
  33. 7.6.2 Pfizer Inc. Business Overview
  34. 7.6.3 Pfizer Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Inc. Human Pain Management Drug Product Portfolio
  36. 7.6.5 Pfizer Inc. Recent Developments
  37. 7.7 GSK plc.
  38. 7.7.1 GSK plc. Company Information
  39. 7.7.2 GSK plc. Business Overview
  40. 7.7.3 GSK plc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GSK plc. Human Pain Management Drug Product Portfolio
  42. 7.7.5 GSK plc. Recent Developments
  43. 7.8 Bayer AG
  44. 7.8.1 Bayer AG Company Information
  45. 7.8.2 Bayer AG Business Overview
  46. 7.8.3 Bayer AG Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bayer AG Human Pain Management Drug Product Portfolio
  48. 7.8.5 Bayer AG Recent Developments
  49. 7.9 Bristol Myers Squibb Co.
  50. 7.9.1 Bristol Myers Squibb Co. Company Information
  51. 7.9.2 Bristol Myers Squibb Co. Business Overview
  52. 7.9.3 Bristol Myers Squibb Co. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bristol Myers Squibb Co. Human Pain Management Drug Product Portfolio
  54. 7.9.5 Bristol Myers Squibb Co. Recent Developments
  55. 7.10 AbbVie Inc. (Allergan plc)
  56. 7.10.1 AbbVie Inc. (Allergan plc) Company Information
  57. 7.10.2 AbbVie Inc. (Allergan plc) Business Overview
  58. 7.10.3 AbbVie Inc. (Allergan plc) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Inc. (Allergan plc) Human Pain Management Drug Product Portfolio
  60. 7.10.5 AbbVie Inc. (Allergan plc) Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Human Pain Management Drug Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
  68. 7.12.1 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Company Information
  69. 7.12.2 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Business Overview
  70. 7.12.3 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Human Pain Management Drug Product Portfolio
  72. 7.12.5 Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) Recent Developments
  73. 7.13 Viatris
  74. 7.13.1 Viatris Company Information
  75. 7.13.2 Viatris Business Overview
  76. 7.13.3 Viatris Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Viatris Human Pain Management Drug Product Portfolio
  78. 7.13.5 Viatris Recent Developments
  79. 7.14 Purdue Pharmaceuticals L.P.
  80. 7.14.1 Purdue Pharmaceuticals L.P. Company Information
  81. 7.14.2 Purdue Pharmaceuticals L.P. Business Overview
  82. 7.14.3 Purdue Pharmaceuticals L.P. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Purdue Pharmaceuticals L.P. Human Pain Management Drug Product Portfolio
  84. 7.14.5 Purdue Pharmaceuticals L.P. Recent Developments
  85. 7.15 Procter & Gamble
  86. 7.15.1 Procter & Gamble Company Information
  87. 7.15.2 Procter & Gamble Business Overview
  88. 7.15.3 Procter & Gamble Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Procter & Gamble Human Pain Management Drug Product Portfolio
  90. 7.15.5 Procter & Gamble Recent Developments
  91. 7.16 Perrigo Company Plc.
  92. 7.16.1 Perrigo Company Plc. Company Information
  93. 7.16.2 Perrigo Company Plc. Business Overview
  94. 7.16.3 Perrigo Company Plc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Perrigo Company Plc. Human Pain Management Drug Product Portfolio
  96. 7.16.5 Perrigo Company Plc. Recent Developments
  97. 7.17 Mallinckrodt Pharmaceuticals
  98. 7.17.1 Mallinckrodt Pharmaceuticals Company Information
  99. 7.17.2 Mallinckrodt Pharmaceuticals Business Overview
  100. 7.17.3 Mallinckrodt Pharmaceuticals Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Mallinckrodt Pharmaceuticals Human Pain Management Drug Product Portfolio
  102. 7.17.5 Mallinckrodt Pharmaceuticals Recent Developments
  103. 7.18 F. Hoffmann-La Roche Ltd.
  104. 7.18.1 F. Hoffmann-La Roche Ltd. Company Information
  105. 7.18.2 F. Hoffmann-La Roche Ltd. Business Overview
  106. 7.18.3 F. Hoffmann-La Roche Ltd. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 F. Hoffmann-La Roche Ltd. Human Pain Management Drug Product Portfolio
  108. 7.18.5 F. Hoffmann-La Roche Ltd. Recent Developments
  109. 7.19 Endo Pharmaceuticals Inc.
  110. 7.19.1 Endo Pharmaceuticals Inc. Company Information
  111. 7.19.2 Endo Pharmaceuticals Inc. Business Overview
  112. 7.19.3 Endo Pharmaceuticals Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Endo Pharmaceuticals Inc. Human Pain Management Drug Product Portfolio
  114. 7.19.5 Endo Pharmaceuticals Inc. Recent Developments
  115. 7.20 Cardinal Health
  116. 7.20.1 Cardinal Health Company Information
  117. 7.20.2 Cardinal Health Business Overview
  118. 7.20.3 Cardinal Health Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Cardinal Health Human Pain Management Drug Product Portfolio
  120. 7.20.5 Cardinal Health Recent Developments
  121. 7.21 Boehringer Ingelheim International GmbH
  122. 7.21.1 Boehringer Ingelheim International GmbH Company Information
  123. 7.21.2 Boehringer Ingelheim International GmbH Business Overview
  124. 7.21.3 Boehringer Ingelheim International GmbH Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Boehringer Ingelheim International GmbH Human Pain Management Drug Product Portfolio
  126. 7.21.5 Boehringer Ingelheim International GmbH Recent Developments
  127. 7.22 Bausch Health Companies Inc.
  128. 7.22.1 Bausch Health Companies Inc. Company Information
  129. 7.22.2 Bausch Health Companies Inc. Business Overview
  130. 7.22.3 Bausch Health Companies Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Bausch Health Companies Inc. Human Pain Management Drug Product Portfolio
  132. 7.22.5 Bausch Health Companies Inc. Recent Developments
  133. 7.23 Amneal Pharmaceuticals
  134. 7.23.1 Amneal Pharmaceuticals Company Information
  135. 7.23.2 Amneal Pharmaceuticals Business Overview
  136. 7.23.3 Amneal Pharmaceuticals Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Amneal Pharmaceuticals Human Pain Management Drug Product Portfolio
  138. 7.23.5 Amneal Pharmaceuticals Recent Developments
  139. 7.24 Abbott Laboratories, Inc.
  140. 7.24.1 Abbott Laboratories, Inc. Company Information
  141. 7.24.2 Abbott Laboratories, Inc. Business Overview
  142. 7.24.3 Abbott Laboratories, Inc. Human Pain Management Drug Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Abbott Laboratories, Inc. Human Pain Management Drug Product Portfolio
  144. 7.24.5 Abbott Laboratories, Inc. Recent Developments
8 North America
  1. 8.1 North America Human Pain Management Drug Revenue (2021-2032)
  2. 8.2 North America Human Pain Management Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Pain Management Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Pain Management Drug Revenue by Type (2027-2032)
  5. 8.3 North America Human Pain Management Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Pain Management Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Pain Management Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Pain Management Drug Revenue by Application (2027-2032)
  9. 8.5 North America Human Pain Management Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Pain Management Drug Revenue by Country
  11. 8.6.1 North America Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Pain Management Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Pain Management Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Human Pain Management Drug Revenue (2021-2032)
  2. 9.2 Europe Human Pain Management Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Pain Management Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Pain Management Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Human Pain Management Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Pain Management Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Pain Management Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Pain Management Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Human Pain Management Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Pain Management Drug Revenue by Country
  11. 9.6.1 Europe Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Pain Management Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Pain Management Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Human Pain Management Drug Revenue (2021-2032)
  2. 10.2 China Human Pain Management Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Human Pain Management Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Human Pain Management Drug Revenue by Type (2027-2032)
  5. 10.3 China Human Pain Management Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Human Pain Management Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Human Pain Management Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Human Pain Management Drug Revenue by Application (2027-2032)
  9. 10.5 China Human Pain Management Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Pain Management Drug Revenue (2021-2032)
  2. 11.2 Asia Human Pain Management Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Pain Management Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Pain Management Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Human Pain Management Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Pain Management Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Pain Management Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Pain Management Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Human Pain Management Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Pain Management Drug Revenue by Country
  11. 11.6.1 Asia Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Pain Management Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Pain Management Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Pain Management Drug Revenue (2021-2032)
  2. 12.2 SAMEA Human Pain Management Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Pain Management Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Pain Management Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Pain Management Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Pain Management Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Pain Management Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Pain Management Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Pain Management Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Pain Management Drug Revenue by Country
  11. 12.6.1 SAMEA Human Pain Management Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Pain Management Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Pain Management Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst